Clinical operations note: how-does-a-cgm-work-a-practical-guide-for-medical-professionals-evaluating-21

Who This Guide Is For (and When to Use It)

If you're specifying or purchasing continuous glucose monitors (CGMs) for a hospital, clinic, or home-health program, this checklist is for you. It covers the basic sensor-reader-transmitter architecture, how each part performs, and—critically—what to verify before you buy.

Why the emphasis on verification? Because I review specs and deliveries for a living—roughly 200+ unique items each year across surgical instruments and monitoring equipment. And I’ll tell you: the difference between spec sheet and real-world performance can cost you more than just a refund.

This isn’t a deep dive into CGM chemistry. It’s a 4-step checklist for understanding how they work, what claims hold up, and what you’ll need to check before they go into patient hands.

Step 1: Understand the Core Sensor Mechanism (Glucose → Signal)

The Basics: A CGM measures glucose levels in the interstitial fluid (ISF) just under the skin, not in the blood directly. Most disposable sensors use a glucose oxidase enzyme on a micro-electrode to catalyze glucose + O₂ → gluconolactone + H₂O₂. The H₂O₂ gets oxidized at the electrode, producing an electrical current proportional to glucose concentration.

What to verify on the spec sheet:

• Enzyme source and byproducts. Some sensors claim "minimal interference" from acetaminophen, ascorbic acid, or uric acid. Look for published interference testing data—ideally peer-reviewed. In Q1 2024, I rejected a vendor's claim because they cited only in-house data with no third-party validation.
• Calibration requirement. Older CGMs required daily fingerstick calibration. Newer models (e.g., Dexcom G7, Abbott FreeStyle Libre 3, Medtronic Simplera) are factory-calibrated and need none. If you're buying for a busy ward, fewer steps per insertion matters.
• Warmup time. Some sensors require 30–60 minutes before delivering readings. That means you can't just insert and go—schedule accordingly. I've seen units rejected by nursing staff in a 24-hour ICU because the 60-minute warmup wasn't flagged in the procurement specs.

Real-world check: Ask the vendor for a sample batch to run parallel ISF vs. venous blood glucose for 48 hours. If the MARD (mean absolute relative difference) > 10%, be skeptical. The claimed MARD on paper is often lower than actual performance under variable patient conditions (dehydration, edema, medication interactions).

Step 2: Map the Transmitter and Receiver Path

The Basics: The sensor connects to a transmitter (often reusable for 90–180 days; some are integrated with the sensor as one disposable unit). The transmitter sends glucose data wirelessly via Bluetooth Low Energy to:

• A dedicated receiver (handheld device)
• A smartphone app (with optional Apple Watch or Fitbit relay)
• A hospital monitoring hub (if using an integrated system, e.g., Medtronic with their insulin pump or Epic EHR integration)

What to verify on the spec sheet:

• Transmitter battery life. If it's rechargeable, how many full charge cycles? If it's disposable, what's the replacement schedule? I discovered the hard way with one brand—the transmitter died at 85% of stated battery life. Their response: "Typical variation." So I now add a 15% safety margin in procurement contracts.
• Data transmission range. In a hospital room with thick walls, Bluetooth range drops. Claimed 10 meters often becomes 5–6 meters through concrete. Check if the system gives a loss-of-signal alarm that didn't just get ignored.
• Interoperability with your EHR. Not all CGMs export data in HL7 or FHIR format. If nurses have to manually log glucose values from a receiver into your system, that's a hidden labor cost. One hospital I worked with switched from an incompatible system to Abbott's LibreView platform—their nurses saved 45 minutes per shift on data entry.

Real-world check: Do a walkthrough with the transmitter and receiver in your actual hospital environment. Walk to the patient room 15 meters away with a concrete wall in between. Does it drop? I've seen a system that claims 30 meters fail at 12 meters inside an older building.

Step 3: Evaluate Accuracy and Interference Handling

The Basics: Accuracy of a CGM is reported as MARD (Mean Absolute Relative Difference). Lower is better. Clinical targets:

• Clarke Error Grid zones A+B: Should be ≥98% for approval.
• MARD: Currently 8–10% for leading models (Abbott Libre 3: ~7.9%; Dexcom G7: ~8.2%; Medtronic Guardian 4: ~9.1%).

What to verify beyond the headline MARD:

• Performance in hypoglycemia range (glucose < 70 mg/dL). Most CGMs are less accurate here. Check the Clarke Grid score specifically for this range. If it's below 95%, consider whether the device triggers appropriate alarms in that zone.
• Interference with IV medications. Some drugs—acetaminophen (paracetamol) in particular—can cause falsely elevated readings. I've had a procurement manager tell me their nurses got false high alerts from post-op patients getting Tylenol. Check the published interference list for every sensor you evaluate.
• Time lag. Interstitial fluid glucose lags blood glucose by 5–15 minutes. For rapid changes (post-meal spikes, insulin corrections), that lag matters. Some systems compensate with predictive algorithms; others don't. Ask for the rise/fall rate calculation in the user manual. If you're planning to use it for real-time insulin delivery (closed-loop), that lag is critical.

Quick rule I use: If the vendor says "MARD < 9%" but can't give you the full dataset by glucose range and by medication interference, I'd request a trial batch. In 2023 I rejected a promising CGM because the MARD in hypoglycemia range was 13.5%—their customer rep tried to dismiss it as "within the general spec." No, it's not.

Step 4: Verify Regulatory Status and Post-Market Data

The Basics: CGMs are Class II medical devices regulated by FDA (in the U.S.) and the European Medicines Agency (EMEA). They typically require 510(k) clearance before market entry.

What to verify:

• Is your specific CGM model FDA-cleared or CE-marked for the intended use? Some sensors are cleared for non-adjunctive use (i.e., you can dose insulin from the reading alone without a fingerstick); others are adjunctive only (must confirm with fingerstick). This changes workflow dramatically. For example, the Dexcom G7 received FDA clearance for non-adjunctive use in 2022; Abbott FreeStyle Libre 2 is also cleared for non-adjunctive use. The Libre 1 was adjunctive only. Verify the current status for your ordering region.
• Post-market surveillance data. Any recalls or corrective actions in the past 3 years? Check FDA MAUDE database or EMEA vigilance reports. In Q2 2024, I flagged a brand that had 4 Class II recalls in 2023 for sensor detachment issues. The sales rep never mentioned it.
• Software and firmware updates. Does the system support over-the-air updates? If not, you're stuck with the firmware version at delivery. I've seen units that required physical replacement of the transmitter to fix a Bluetooth pairing bug—wasted 3 days of inventory.

Real-world check: Ask for the FDA 510(k) summary letter (available on the FDA website). Cross-check the model number on your order. I've had a vendor send a slightly different model than quoted—"same thing, just an older revision"—not the same.

Important Caveats (Stuff They Don't Always Tell You)

Sensor lifespan is shorter than stated for some patients. The manufacturer says 14 days for a sensor. But adhesive failure happens sooner in sweaty or active patients (or in hot climates). One study showed 25% of Libre 3 sensors failed before day 10 in summer conditions (Source: Diabetes Technology & Therapeutics, 2023). If your patient population is active or lives in a warm region, expect reduced lifespan.

The "no calibration needed" claim is conditional. Factory-calibrated sensors are tested under standard conditions. For patients with significant edema, impaired circulation, or undergoing dialysis, the lag can increase. Another hidden variable: altitude changes. If your patients fly frequently or live in high-altitude regions, the oxygen pressure change can affect sensor readings. I saw a 12% deviation during a trial in a Denver hospital (vs. sea-level calibration standard). The manufacturer's response: "We don't test at altitude." So add that to your procurement criteria.

Data privacy and HIPAA compliance. If the CGM app and cloud platform store patient data, verify their HIPAA Business Associate Agreement (BAA) status and data encryption policies. In 2023, the FTC issued a warning to one CGM app vendor for collecting user data without explicit consent. Per FTC guidelines (ftc.gov), health data stored on consumer devices must follow FTC Health Breach Notification Rule if the data is accessed without authorization.

Bottom line: The sensor chemistry is similar across brands—glucose oxidase on a micro-electrode—but real-world reliability and integration matter just as much as the MARD number. Walk through these 4 steps with every vendor before you buy.

Prices as of July 2025; verify current rates with your distributor. Regulatory information is for general guidance; consult FDA or EMEA for current requirements.